What Is the Treatment for Cytomegalovirus Gastroenteritis and Hepatitis?
Cytomegalovirus (CMV) can cause significant gastrointestinal disease — including colitis and esophagitis — as well as hepatitis. Effective management requires directed antiviral therapy aimed at eliminating active infection and achieving full resolution of signs and symptoms.
The preferred initial strategy involves intravenous antiviral therapy. Once a patient can adequately absorb and tolerate oral medications, a step-down to an oral antiviral agent is an established option. The complete drug selection, sequencing, and criteria for switching are specified in the full protocol.
The primary therapeutic goal is resolution of gastrointestinal signs and symptoms of CMV disease. Therapy duration is guided by clinical response; the protocol defines the specific continuation criteria and endpoints.
- Ganciclovir 5 mg/kg IV every 12 hours (AI); may switch to valganciclovir 900 mg PO every 12 hours once the patient can absorb and tolerate PO therapy (AIII)
- IV ganciclovir is the therapy of choice (AI) and can be switched to oral valganciclovir once the person can tolerate and absorb oral medications, extrapolated from randomized, clinical trial data showing non-inferiority of oral valganciclovir for treatment of CMV disease in people receiving a solid organ transplant (SOT) (AIII).
- 21–42 days or until signs and symptoms have resolved (AIII)
- For patients who have colitis or esophagitis, anti-CMV therapy for 21 to 42 days is recommended until resolution of signs and symptoms (AIII), based on data that CMV persists with only 14 days of treatment for CMV colitis in people with HIV.